BACKGROUND: Early management of patients with patent infarct-related artery (IRA) and optimal ST resolution in ST elevation myocardial infarction (STEMI) has never been assessed. We compared immediate vs delayed PCI in these patients. METHODS: Matched comparison of immediate vs delayed (24 h) PCI in STEMI patients presenting with patent IRA, thrombus-containing lesion and ST resolution >or=70%. Patients were matched for duration of symptoms, intervention type, angiographic data, diabetes. Patients in immediate PCI group received standard therapy in the cathlab. Patients in delayed PCI group received dual antiplatelet therapy, antithrombins, and GPIIb-IIIa inhibitors until PCI. Primary endpoint was procedural success. Secondary endpoints were enzyme release and in-hospital adverse events. RESULTS: Seventy-eight patients were included: 39 per group. Average age 62 years, 75% males. There was a significantly higher procedural success rate in the delayed PCI group (95% success, Vs. 77% in the immediate group, P = 0.008). Initial thrombus burden score did not differ between immediate and delayed PCI groups, but improved significantly in the delayed group between baseline angiography and time of PCI (P = 0.039). There was no difference in major adverse events or bleeding complications between groups. Peak CK levels were significantly higher in the immediate versus delayed PCI group (P = 0.02), although there was no difference between groups in peak CK-MB, peak troponin, or peak CK-MB ratio. CONCLUSION: Our data suggest that in STEMI patients with patent IRA, optimal ST-segment resolution, and thrombus-containing lesion, deferred PCI when patients are given dual antiplatelet therapy, antithrombin agents, and GPIIb-IIIa inhibitors results in a higher procedural success rate, without an increased risk of MACE.
BACKGROUND: Early management of patients with patent infarct-related artery (IRA) and optimal ST resolution in ST elevation myocardial infarction (STEMI) has never been assessed. We compared immediate vs delayed PCI in these patients. METHODS: Matched comparison of immediate vs delayed (24 h) PCI in STEMI patients presenting with patent IRA, thrombus-containing lesion and ST resolution >or=70%. Patients were matched for duration of symptoms, intervention type, angiographic data, diabetes. Patients in immediate PCI group received standard therapy in the cathlab. Patients in delayed PCI group received dual antiplatelet therapy, antithrombins, and GPIIb-IIIa inhibitors until PCI. Primary endpoint was procedural success. Secondary endpoints were enzyme release and in-hospital adverse events. RESULTS: Seventy-eight patients were included: 39 per group. Average age 62 years, 75% males. There was a significantly higher procedural success rate in the delayed PCI group (95% success, Vs. 77% in the immediate group, P = 0.008). Initial thrombus burden score did not differ between immediate and delayed PCI groups, but improved significantly in the delayed group between baseline angiography and time of PCI (P = 0.039). There was no difference in major adverse events or bleeding complications between groups. Peak CK levels were significantly higher in the immediate versus delayed PCI group (P = 0.02), although there was no difference between groups in peak CK-MB, peak troponin, or peak CK-MB ratio. CONCLUSION: Our data suggest that in STEMI patients with patent IRA, optimal ST-segment resolution, and thrombus-containing lesion, deferred PCI when patients are given dual antiplatelet therapy, antithrombin agents, and GPIIb-IIIa inhibitors results in a higher procedural success rate, without an increased risk of MACE.
Authors: Ugo Limbruno; Andrea Micheli; Marco De Carlo; Giovanni Amoroso; Roberta Rossini; Caterina Palagi; Vitantonio Di Bello; Anna Sonia Petronio; Gabriella Fontanini; Mario Mariani Journal: Circulation Date: 2003-06-30 Impact factor: 29.690
Authors: Benjamin M Scirica; Marc S Sabatine; David A Morrow; C Michael Gibson; Sabina A Murphy; Stephen D Wiviott; Robert P Giugliano; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2006-06-12 Impact factor: 24.094
Authors: Marc S Sabatine; David A Morrow; Gilles Montalescot; Mikael Dellborg; Jose L Leiva-Pons; Matyas Keltai; Sabina A Murphy; Carolyn H McCabe; C Michael Gibson; Christopher P Cannon; Elliott M Antman; Eugene Braunwald Journal: Circulation Date: 2005-11-15 Impact factor: 29.690
Authors: E M Ohman; R M Califf; E J Topol; R Candela; C Abbottsmith; S Ellis; K N Sigmon; D Kereiakes; B George; R Stack Journal: Circulation Date: 1990-09 Impact factor: 29.690
Authors: Gregg W Stone; John Webb; David A Cox; Bruce R Brodie; Mansoor Qureshi; Anna Kalynych; Mark Turco; Heinz P Schultheiss; Daniel Dulas; Barry D Rutherford; David Antoniucci; Mitchell W Krucoff; Raymond J Gibbons; Denise Jones; Alexandra J Lansky; Roxana Mehran Journal: JAMA Date: 2005-03-02 Impact factor: 56.272
Authors: Jorrit Lemkes; Robin Nijveldt; Aernout M Beek; Paul Knaapen; Alexander Hirsch; Joost Meijers; Cor P Allaart; Albert van Rossum; Niels van Royen Journal: J Cardiovasc Transl Res Date: 2014-05-30 Impact factor: 4.132
Authors: Lumir Koc; Monika Mikolaskova; Tomas Novotny; Jiri Parenica; Jan Kanovsky; Tomas Ondrus; Maria Holicka; Martin Poloczek; Jiri Jarkovsky; Marek Malik; Petr Kala Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2021-02-04 Impact factor: 1.245